Skip to main content

Advertisement

SpringerLink
Log in

Lipidic extract of whole tomato reduces hyperplasia, oxidative stress and inflammation on testosterone-induced BPH in obese rats

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Tomato is an important source of lycopene, a carotenoid that has been emerging as a natural preventive agent for prostate disease. Moreover, tomato contains other components with a wide range of physiological properties, but their potential beneficial effects on prostatic hyperplasia (PH) during obesity have not been completely established. In this study, we compared the effect of a lipidic extract of tomato saladette (STE) with Serenoa repens (SR) on obese rats with PH.

Methods

Forty-eight Wistar rats were divided in Control (C) and Obese (Ob) treated without (n = 12) and with (n = 36) testosterone enanthate (TE), once a week for 8 weeks to induce PH. After 4 weeks, SR and STE were administered. Biochemical parameters, oxidative stress markers and inflammatory cytokines production were determined.

Results

TE increased prostate weight and caused prostatic hyperplasia in C group, and these effects were exacerbated by obesity. SR and STE reverted the increase in prostate weight and hyperplasia caused by TE in C and Ob groups. Obesity increased LDL, TGs, NOx and MAD, but decreased HDLc, GSx, SOD and CAT. SR reverted the effects of obesity, but these were significantly reduced and HDLc increased with STE. Obesity and TE increased TNFα, IL-1β and IL-6 levels, but these were partially reverted by STE compared with SR.

Conclusions

Excess of fat tissue increases the alterations by PH. STE diminishes these alterations compared with SR, suggesting its beneficial effect to improve prostate function. Whole tomato lipid extract could serve as sole therapy or as an adjunct to pharmacological treatment for PH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Mraz M, Haluzik M (2014) The role of adipose tissue immune cells in obesity and low-grade inflammation. J Endocrinol 222(3):R113–R127. https://doi.org/10.1530/JOE-14-0283

    Article  CAS  PubMed  Google Scholar 

  2. Foster CS (2000) Pathology of benign prostatic hyperplasia. Prostate Suppl 9:4–14. https://doi.org/10.1002/1097-0045(2000)45:9+%3c4::aid-pros3%3e3.0.co;2-q

    Article  CAS  PubMed  Google Scholar 

  3. García-Flórez M, Oliveira CA, Carvalho HF (2005) Early effects of estrogen on the rat ventral prostate. Braz J Med Biol Res 38(4):487–497. https://doi.org/10.1590/s0100-879x2005000400002

    Article  PubMed  Google Scholar 

  4. Chughtai B, Forde JC, Thomas DD et al (2016) Benign prostatic hyperplasia. Nat Rev Dis Primers 2:16031. https://doi.org/10.1038/nrdp.2016.31

    Article  PubMed  Google Scholar 

  5. Langan RC (2019) Benign prostatic hyperplasia. Prim Care 46(2):223–232. https://doi.org/10.1016/j.pop.2019.02.003

    Article  PubMed  Google Scholar 

  6. Cicero AFG, Allkanjari O, Busetto GM et al (2019) Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl. https://doi.org/10.4081/aiua.2019.3.139

    Article  PubMed  Google Scholar 

  7. van Breemen RB, Pajkovic N (2008) Multitargeted therapy of cancer by lycopene. Cancer Lett 269(2):339–351. https://doi.org/10.1016/j.canlet.2008.05.016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Basu A, Imrhan V (2007) Tomatoes versus lycopene in oxidative stress and carcinogenesis: conclusions from clinical trials. Eur J Clin Nutr 61(3):295–303. https://doi.org/10.1038/sj.ejcn.1602510

    Article  CAS  PubMed  Google Scholar 

  9. Chen J, Song Y, Zhang L (2013) Lycopene/tomato consumption and the risk of prostate cancer: a systematic review and meta-analysis of prospective studies. J Nutr Sci Vitaminol (Tokyo) 59(3):213–223. https://doi.org/10.3177/jnsv.59.213

    Article  CAS  PubMed  Google Scholar 

  10. Clinton SK (2005) Tomatoes or lycopene: a role in prostate carcinogenesis? J Nutr 135(8):2057S-2059S. https://doi.org/10.1093/jn/135.8.2057S

    Article  CAS  PubMed  Google Scholar 

  11. Limpens J, Schröder FH, de Ridder CMA et al (2006) Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J Nutr 136(5):1287–1293. https://doi.org/10.1093/jn/136.5.1287

    Article  CAS  PubMed  Google Scholar 

  12. Chen L, Stacewicz-Sapuntzakis M, Duncan C et al (2001) Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. JNCI J Natl Cancer Inst 93(24):1872–1879. https://doi.org/10.1093/jnci/93.24.1872

    Article  CAS  PubMed  Google Scholar 

  13. Mohanty NK, Saxena S, Singh UP et al (2005) Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urol Oncol 23(6):383–385. https://doi.org/10.1016/j.urolonc.2005.05.012

    Article  CAS  PubMed  Google Scholar 

  14. Arts IC, Hollman PC (2005) Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 81(1 Suppl):317S-325S. https://doi.org/10.1093/ajcn/81.1.317S

    Article  CAS  PubMed  Google Scholar 

  15. Huxley RR, Neil HAW (2003) The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr 57(8):904–908. https://doi.org/10.1038/sj.ejcn.1601624

    Article  CAS  PubMed  Google Scholar 

  16. Yang XB, Zhao Y, Yang Y, Ruan Y (2008) Isolation and characterization of immunostimulatory polysaccharide from and herb tea, Gynostemma pentaphyllum Makino. J Agric Food Chem 56:6905–6909. https://doi.org/10.1021/jf801101u

    Article  CAS  PubMed  Google Scholar 

  17. Paubert-Braquet M, Cousse H, Raynaud JP et al (1998) Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 33(3):340–347. https://doi.org/10.1159/000019570

    Article  CAS  PubMed  Google Scholar 

  18. Silvestri I, Cattarino S, Aglianò A et al (2013) Effect of Serenoa repens ( Permixon ®) on the expression of inflammation-related genes : analysis in primary cell cultures of human prostate carcinoma. J Inflamm 10:11. https://doi.org/10.1186/1476-9255-10-11

    Article  Google Scholar 

  19. Perry R, Milligan G, Anderson P et al (2012) Real-world use of Permixon® in benign prostatic hyperplasia–determining appropriate monotherapy and combination treatment. Adv Ther 29(6):538–550. https://doi.org/10.1007/s12325-012-0024-x

    Article  CAS  PubMed  Google Scholar 

  20. Allkanjari O, Vitalone A (2015) What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci 126:42–56. https://doi.org/10.1016/j.lfs.2015.01.023

    Article  CAS  PubMed  Google Scholar 

  21. Levin RM, Das AK (2000) A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res 28(3):201–209. https://doi.org/10.1007/s002409900098

    Article  CAS  PubMed  Google Scholar 

  22. Governa P, Giachetti D, Biagi M et al (2016) Hypothesis on Serenoa Repens (Bartram) small extract inhibition of prostatic 5α-reductase x-ray structure. Peer J 4:e2698. https://doi.org/10.7717/peerj.2698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Colado-Velázquez JI, Mailloux-Salinas P, Medina-Contreras J et al (2015) Effect of Serenoa Repens on oxidative stress, inflammatory and growth factors in obese Wistar rats with benign prostatic hyperplasia. Phytother Res 10:1525–1531. https://doi.org/10.1002/ptr.5406

    Article  Google Scholar 

  24. Minutoli L, Bitto A, Squadrito F et al (2013) Serenoa Repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia. Curr Med Chem 20(10):1306–1312. https://doi.org/10.2174/0929867311320100007

    Article  CAS  PubMed  Google Scholar 

  25. Di Silverio F, Bosman C, Salvatori M et al (2005) Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 47(1):72–78. https://doi.org/10.1016/j.eururo.2004.08.024

    Article  CAS  PubMed  Google Scholar 

  26. Carraro JC, Raynaud JP, Koch G et al (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29(4):231–240. https://doi.org/10.1002/(SICI)1097-0045(199610)29:4%3c231

    Article  PubMed  Google Scholar 

  27. Geavlete P, Multescu R, Geavlete B (2011) Serenoa repens extract in the treatment of benign prostatic hyperplasia. Ther Adv Urol 3(4):193–198. https://doi.org/10.1177/1756287211418725

    Article  PubMed  PubMed Central  Google Scholar 

  28. Espinosa-Juárez J, Colado-Velázquez JIII, Mailoux-Salinas P et al (2017) Beneficial effects of lipidic extracts of saladette tomato pomace and Serenoa repens on prostate and bladder health in obese male Wistar rats. J Sci Food Agric 97(13):4451–4458. https://doi.org/10.1002/jsfa.8308

    Article  CAS  PubMed  Google Scholar 

  29. Altavilla D, Bitto A, Polito F et al (2011) The combination of Serenoa Repens, Selenium and Lycopene is more effective than Serenoa repens alone to prevent hormone dependent prostatic growth. J Urol 186:1524–1529. https://doi.org/10.1016/j.juro.2011.05.049

    Article  CAS  PubMed  Google Scholar 

  30. Colado-Velazquez JIII et al. (2021) Extracto de Tomate (Lycopersicum esculentum) para el tratamiento de hiperplasia de próstata en obesidad. (Mexico, Mexico Patent No. 380295). Mexicano de la Protección Industrial. https://www.gob.mx

  31. Fish WW, Perkins-Veazie P, Collins JK (2002) A quantitative assay for lycopene that utilizes reduced volumes of organic solvents. J Food Compos Anal 15(3):309–317. https://doi.org/10.1006/jfca.2002.1069

    Article  CAS  Google Scholar 

  32. Miranda KM, Espey MG, Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5(1):62–71. https://doi.org/10.1006/niox.2000.0319

    Article  CAS  PubMed  Google Scholar 

  33. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358. https://doi.org/10.1016/0003-2697(79)90738-3

    Article  CAS  PubMed  Google Scholar 

  34. Lee S, Min HG, Choi SH et al (2006) Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring) 14(1):172–179. https://doi.org/10.1038/oby.2006.21

    Article  PubMed  Google Scholar 

  35. Kristal AR, Arnold KB, Schenk JM et al (2007) Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 177(4):1395–1400. https://doi.org/10.1016/j.juro.2006.11.065

    Article  PubMed  Google Scholar 

  36. Lokeshwar SD, Harper BT, Webb E et al (2019) Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 8(5):529–539. https://doi.org/10.21037/tau.2019.10.01

    Article  PubMed  PubMed Central  Google Scholar 

  37. Patel ND, Parsons JK (2014) Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol 30(2):170–176. https://doi.org/10.4103/0970-1591.126900

    Article  PubMed  PubMed Central  Google Scholar 

  38. Lee RK, Chung D, Chughtai B, Te AE, Kaplan SA (2012) Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int 110(4):540–545. https://doi.org/10.1111/j.1464-410X.2011.10819.x

    Article  PubMed  Google Scholar 

  39. Parsons JK, Carter HB, Partin AW et al (2006) Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91(7):2562–2568. https://doi.org/10.1210/jc.2005-2799

    Article  CAS  PubMed  Google Scholar 

  40. Batai K, Phung M, Bell R et al (2021) Correlation between body mass index and prostate volume in benign prostatic hyperplasia patients undergoing holmium enucleation of the prostate surgery. BMC Urol 21(1):88. https://doi.org/10.1186/s12894-020-00753-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. El-Sherbiny M, El-Shafey M, El-Din El-Agawy MS et al (2021) Diacerein ameliorates testosterone-induced benign prostatic hyperplasia in rats: Effect on oxidative stress, inflammation and apoptosis. Int Immunopharmacol 100:108082. https://doi.org/10.1016/j.intimp.2021.108082

    Article  CAS  PubMed  Google Scholar 

  42. Wang L, Hou Y, Wang R et al (2021) Inhibitory effect of astaxanthin on testosterone-induced benign prostatic hyperplasia in rats. Mar Drugs 19(12):652. https://doi.org/10.3390/md19120652

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chen Z, Miao L, Gao X, Wang G, Xu Y (2015) Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes. Int J Clin Exp Med 8(7):11289–11294

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Shih HJ, Huang CJ, Lin JA et al (2018) Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia. Prostate 78(2):113–120. https://doi.org/10.1002/pros.23451

    Article  CAS  PubMed  Google Scholar 

  45. Jerde TJ, Bushman W (2009) IL-1 induces IGF-dependent epithelial proliferation in prostate development and reactive hyperplasia. Sci Signal 2(86):ra49. https://doi.org/10.1126/scisignal.2000338

    Article  PubMed  PubMed Central  Google Scholar 

  46. Corona G, Vignozzi L, Rastrelli G et al (2014) Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. https://doi.org/10.1155/2014/329456

    Article  PubMed  PubMed Central  Google Scholar 

  47. Nandy PR, Saha S (2016) Association between components of metabolic syndrome and prostatic enlargement: an Indian perspective. Med J Armed Forces India 72(4):350–355. https://doi.org/10.1016/j.mjafi.2016.07.005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Wan X, Yang Z, Ji H et al (2021) Effects of lycopene on abdominal fat deposition, serum lipids levels and hepatic lipid metabolism-related enzymes in broiler chickens. Anim Biosci 34(3):385–392. https://doi.org/10.5713/ajas.20.0432

    Article  CAS  PubMed  Google Scholar 

  49. Hosseini-Vashan SJ, Golian A, Yaghobfar A (2016) Growth, immune, antioxidant, and bone responses of heat stress-exposed broilers fed diets supplemented with tomato pomace. Int J Biometeorol 60:1183–1192. https://doi.org/10.1007/s00484-015-1112-9

    Article  CAS  PubMed  Google Scholar 

  50. Silva SA, Gobbo MG, Pinto-Fochi ME et al (2015) Prostate hyperplasia caused by long-term obesity is characterized by high deposition of extracellular matrix and increased content of MMP-9 and VEGF. Int J Exp Pathol 96(1):21–30. https://doi.org/10.1111/iep.12107

    Article  CAS  PubMed  Google Scholar 

  51. Timms BG, Hofkamp LE (2011) Prostate development and growth in benign prostatic hyperplasia. Differentiation 82(4–5):173–183. https://doi.org/10.1016/j.diff.2011.08.002

    Article  CAS  PubMed  Google Scholar 

  52. Ribeiro DL, Pinto ME, Maeda SY et al (2012) High fat-induced obesity associated with insulin-resistance increases FGF-2 content and causes stromal hyperplasia in rat ventral prostate. Cell Tissue Res 349(2):577–588. https://doi.org/10.1007/s00441-012-1420-x

    Article  CAS  PubMed  Google Scholar 

  53. Cohen PG (2009) Benign prostatic hyperplasia: the hypogonadal-obesity-prostate connection. Med Hypotheses 73(2):142–143. https://doi.org/10.1016/j.mehy.2009.03.013

    Article  CAS  PubMed  Google Scholar 

  54. Ribeiro DL, Pinto ME, Rafacho A et al (2012) High-fat diet obesity associated with insulin resistance increases cell proliferation, estrogen receptor, and PI3K proteins in rat ventral prostate. J Androl 33(5):854–865. https://doi.org/10.2164/jandrol.111.016089

    Article  CAS  PubMed  Google Scholar 

  55. Koerner A, Kratzsch J, Kiess W (2005) Adipocytokines: leptin–the classical, resistin–the controversical, adiponectin–the promising, and more to come. Best Pract Res Clin Endocrinol Metab 19(4):525–546. https://doi.org/10.1016/j.beem.2005.07.008

    Article  CAS  PubMed  Google Scholar 

  56. Leze E, Alves-Pereira JL, Colli S et al (2012) Leptin regulates proliferation and apoptosis in human prostate. Sci World J 2012:842301. https://doi.org/10.1100/2012/842301

    Article  CAS  Google Scholar 

  57. Vikram A, Kushwaha S, Jena GB (2011) Relative influence of testosterone and insulin in the regulation of prostatic cell proliferation and growth. Steroids 76(4):416–423. https://doi.org/10.1016/j.steroids.2010.12.014

    Article  CAS  PubMed  Google Scholar 

  58. Takeda M, Tang R, Shapiro E et al (1995) Effects of nitric oxide on human and canine prostates. Urology 45(3):440–446. https://doi.org/10.1016/S0090-4295(99)80013-2

    Article  CAS  PubMed  Google Scholar 

  59. Roumeguère T, Sfeir J, El Rassy E et al (2017) Oxidative stress and prostatic diseases. Mol Clin Oncol 7(5):723–728. https://doi.org/10.3892/mco.2017.1413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Shoieb SM, Esmat A, Khalifa AE, Abdel-Naim AB (2018) Chrysin attenuates testosterone-induced benign prostate hyperplasia in rats. Food Chem Toxicol 111:650–659. https://doi.org/10.1016/j.fct.2017.12.017

    Article  CAS  PubMed  Google Scholar 

  61. Rao AV, Agarwal S (2000) Role of antioxidant lycopene in cancer and heart disease. J Am Coll Nutr 19(5):563–569. https://doi.org/10.1080/07315724.2000.10718953

    Article  CAS  PubMed  Google Scholar 

  62. Story EN, Kopec RE, Schwartz SJ et al (2010) An update on the health effects of tomato lycopene. Annu Rev Food Sci Technol 1:189–210. https://doi.org/10.1146/annurev.food.102308.124120

    Article  CAS  PubMed  Google Scholar 

  63. Wang H, Leung LK (2010) The carotenoid lycopene differentially regulates phase I and II enzymes in dimethylbenz[a]anthracene-induced MCF-7 cells. Nutrition 26(11–12):1181–1187. https://doi.org/10.1016/j.nut.2009.11.013

    Article  CAS  PubMed  Google Scholar 

  64. Cormio L, Calò B, Falagario U, Iezzi M, Lamolinara A, Vitaglione P, Silecchia G, Carrieri G, Fogliano V, Iacobelli S, Natali PG, Piantelli M (2021) Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study. J Transl Med 19(1):24. https://doi.org/10.1186/s12967-020-02684-3.8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Rho J, Seo CS, Park HS et al (2020) Asteris Radix et Rhizoma suppresses testosterone-induced benign prostatic hyperplasia in rats by regulating apoptosis and inflammation. J Ethnopharmacol 12(255):112779. https://doi.org/10.1016/j.jep.2020.112779

    Article  CAS  Google Scholar 

  66. Abdel-Naim AB, Neamatallah T, Eid BG, Esmath A et al (2018) 2-methoxyestradiol attenuates testosterone-induced benign prostate hyperplasia in rats through inhibition of HIF-1α/TGF-β/Smad2 axis. Oxid Med Cell Longev. https://doi.org/10.1155/2018/4389484

    Article  PubMed  PubMed Central  Google Scholar 

  67. Csikós E, Horváth A, Ács K et al (2021) Treatment of benign prostatic hyperplasia by natural drugs. Molecules 26(23):7141. https://doi.org/10.3390/molecules26237141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Riso P, Visioli F, Grande S et al (2006) Effect of a tomato-based drink on markers of inflammation, immunomodulation, and oxidative stress. J Agric Food Chem 54(7):2563–2566. https://doi.org/10.1021/jf053033c

    Article  CAS  PubMed  Google Scholar 

  69. Zhao Q, Yang F, Meng L et al (2020) Lycopene attenuates chronic prostatitis/chronic pelvic pain syndrome by inhibiting oxidative stress and inflammation via the interaction of NF-κB, MAPKs, and Nrf2 signaling pathways in rats. Andrology 3:747–755. https://doi.org/10.1111/andr.12747.ers

    Article  Google Scholar 

Download references

Acknowledgements

The research was carried out with partial support by CONACYT postgraduate fellowship #96606.

Author information

Authors and Affiliations

  1. Depto. Farmacobiología, Cinvestav-IPN, Calz. de los Tenorios 235, Col. Granjas Coapa, 14330, México, Mexico

    Juventino III Colado-Velázquez, Patrick Mailloux-Salinas, David Julian Arias-Chávez, Jessica Ledesma-Aparicio, Norma Leticia Gómez-Viquez & Guadalupe Bravo

  2. Autonomous University of the West, Unidad Regional Culiacán, Sinaloa, Mexico

    Juventino III Colado-Velázquez & Gabriel Noris Sarabia

  3. Lab. de Metabolismo I, Departamento de Fisiología “Dr. Mauricio Russek Berman”, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, México, Mexico

    Edgard Cano-Europa

Authors
  1. Juventino III Colado-Velázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Mailloux-Salinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Julian Arias-Chávez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jessica Ledesma-Aparicio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Norma Leticia Gómez-Viquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Edgard Cano-Europa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gabriel Noris Sarabia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Guadalupe Bravo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

G.B., JIIIC.V. and P.M.S contributed to the study design and reviewed the manuscript. P.M.S, J.L.A., D.J.A.CH. and G.N.S. contributed to experimental work and analyzed the data. E.C.E., D.J.A.CH. and N.L.G.V. contributed to discussion and approved the version to be published.

Corresponding author

Correspondence to Guadalupe Bravo.

Ethics declarations

Conflict of interest

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Colado-Velázquez, J., Mailloux-Salinas, P., Arias-Chávez, D.J. et al. Lipidic extract of whole tomato reduces hyperplasia, oxidative stress and inflammation on testosterone-induced BPH in obese rats. Int Urol Nephrol 55, 529–539 (2023). https://doi.org/10.1007/s11255-022-03383-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-022-03383-2

Keywords

Search

Navigation